{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:58:12Z","timestamp":1794434292990,"version":"4.9.1"},"reference-count":44,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The relationship between type 2 diabetes mellitus (T2DM) and cardiovascular (CV) morbidity and mortality is well-established. Ventricular arrhythmias (VA) are frequently diagnosed in patients with T2DM, especially in those with associated coronary syndrome, non-ischemic dilated cardiomyopathy (NIDCM), and heart failure (HF). In these patients, VA and sudden cardiac arrest (SCA) are considered responsible for more than 50% of CV deaths. Newly developed glucose-lowering agents (GLA) seem not only to ameliorate CV morbidity and mortality, but also to reduce the risk of VA and SCA. Materials and Methods: We researched the medical literature on Pub-Med, Clarivate, and Google Scholar for original articles published in the last five years that debated the possible effects of various GLA on ventricular arrhythmias. Results: We identified nineteen original articles, nine of them debating the antiarrhythmic effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i); Conclusions: The results concerning the impact of various GLA on VA\/SCA were heterogeneous depending on the pharmacological class studied, with some of them having neutral, positive, or negative effects. Although it appears that SGLT2i reduces the prevalence of atrial fibrillation and SCA, their effect on VA is not conclusive.<\/jats:p>","DOI":"10.3390\/medicina59101760","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T04:17:19Z","timestamp":1696220239000},"page":"1760","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Associations between Oral Glucose-Lowering Agents and Increased Risk for Life-Threatening Arrhythmias in Patients with Type 2 Diabetes Mellitus\u2014A Literature Review"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-741X","authenticated-orcid":false,"given":"Cristina","family":"Tudoran","sequence":"first","affiliation":[{"name":"Department VII, Internal Medicine II, Discipline of Cardiology, University of Medicine and Pharmacy \u201cVictor Babes\u201d Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania"},{"name":"Center of Molecular Research in Nephrology and Vascular Disease, Faculty of the University of Medicine and Pharmacy \u201cVictor Babes\u201d Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania"},{"name":"County Emergency Hospital \u201cPius Brinzeu\u201d, L. Rebreanu, Nr. 156, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Tudoran","sequence":"additional","affiliation":[{"name":"County Emergency Hospital \u201cPius Brinzeu\u201d, L. Rebreanu, Nr. 156, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-0000","authenticated-orcid":false,"given":"Catalina","family":"Giurgi-Oncu","sequence":"additional","affiliation":[{"name":"County Emergency Hospital \u201cPius Brinzeu\u201d, L. Rebreanu, Nr. 156, 300723 Timisoara, Romania"},{"name":"Discipline of Psychiatry, Department of Neuroscience, University of Medicine and Pharmacy \u201cVictor Babes\u201d Timisoara, Eftimie Murgu Place Nr. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-0960","authenticated-orcid":false,"given":"Ahmed","family":"Abu-Awwad","sequence":"additional","affiliation":[{"name":"County Emergency Hospital \u201cPius Brinzeu\u201d, L. Rebreanu, Nr. 156, 300723 Timisoara, Romania"},{"name":"Department XV, Discipline of Orthopedics\u2014Traumatology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"},{"name":"Research Center University Professor Doctor Teodor \u0218ora, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6793-5361","authenticated-orcid":false,"given":"Simona-Alina","family":"Abu-Awwad","sequence":"additional","affiliation":[{"name":"County Emergency Hospital \u201cPius Brinzeu\u201d, L. Rebreanu, Nr. 156, 300723 Timisoara, Romania"},{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5960-9043","authenticated-orcid":false,"given":"Florica","family":"Voi\u0163\u0103-Mekere\u015f","sequence":"additional","affiliation":[{"name":"Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 Universitatii Street, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.31083\/j.rcm2202038","article-title":"Clinical Overview of Diabetes Mellitus as a Risk Factor for Cardiovascular Death","volume":"22","author":"Abuelgasim","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ. Res."},{"key":"ref_4","first-page":"e11100","article-title":"Diabetic Cardiomyopathy as a Clinical Entity: Is It a Myth?","volume":"12","author":"Zaveri","year":"2020","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/2047487319885461","article-title":"Heart Failure and Its Complications in Patients with Diabetes: Mounting Evidence for a Growing Burden","volume":"26","author":"Ferrini","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5913374","DOI":"10.1155\/2022\/5913374","article-title":"Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy","volume":"2022","author":"Tang","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12933-018-0768-y","article-title":"Type 2 Diabetes Is Independently Associated with All-Cause Mortality Secondary to Ventricular Tachyarrhythmias","volume":"17","author":"Weidner","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-020-01048-x","article-title":"The Association between SGLT2 Inhibitors and New-Onset Arrhythmias: A Nationwide Population-Based Longitudinal Cohort Study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v12.i1.1","article-title":"Diabetes-Induced Changes in Cardiac Voltage-Gated Ion Channels","volume":"12","author":"Ozturk","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3389\/fphys.2018.01517","article-title":"Proarrhythmic Remodeling of Calcium Homeostasis in Cardiac Disease; Implications for Diabetes and Obesity","volume":"9","author":"Hamilton","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"687256","DOI":"10.3389\/fphar.2021.687256","article-title":"Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes","volume":"12","author":"Gallego","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1111\/dom.13348","article-title":"Association of Hypoglycaemia and Risk of Cardiac Arrhythmia in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"20","author":"Fitzpatrick","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_14","first-page":"20","article-title":"Association between Sodium\u2013Glucose Cotransporter-2 Inhibitors and Risk of Sudden Cardiac Death or Ventricular Arrhythmias: A Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"EP Eur."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 Inhibitors with Arrhythmias and Sudden Cardiac Death in Patients with Type 2 Diabetes or Heart Failure: A Meta-Analysis of 34 Randomized Controlled Trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101405","DOI":"10.1016\/j.diabet.2022.101405","article-title":"Glucose-Lowering Agents and Risk of Ventricular Arrhythmias and Sudden Cardiac Death: A Comprehensive Review Ranging from Sulphonylureas to SGLT2 Inhibitors","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., and von Lewinski, D. (2022). SGLT2 Inhibitors and Their Antiarrhythmic Properties. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031678"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12933-020-00999-5","article-title":"The Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia with Rosiglitazone versus Pioglitazone: Real-World Evidence on Thiazolidinedione Safety","volume":"19","author":"Leonard","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/cpt.2570","article-title":"Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies","volume":"111","author":"Islam","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_20","first-page":"1052","article-title":"Impact of Sodium-Glucose Co-Transporter Inhibitors on Cardiac Autonomic Function and Mortality: No Time to Die","volume":"24","author":"Lim","year":"2022","journal-title":"EP Eur."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/dom.14854","article-title":"Incident Heart Failure, Arrhythmias and Cardiovascular Outcomes with Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor Use in Patients with Diabetes: Insights from a Global Federated Electronic Medical Record Database","volume":"25","author":"Fawzy","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 Inhibitors Reduce Sudden Cardiac Death Risk in Heart Failure: Meta-analysis of Randomized Clinical Trials","volume":"34","author":"Oates","year":"2023","journal-title":"Cardiovasc. Electrophysiol."},{"key":"ref_23","first-page":"pvad033","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors Compared with Glucagon-like-Peptide-1 Receptor Agonists and out-of-Hospital Cardiac Arrest in Type 2 Diabetes: A Nationwide Nested Case-Control Study","volume":"9","author":"Halili","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2337\/dc17-0294","article-title":"Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia","volume":"41","author":"Leonard","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin Is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in People with Type 2 Diabetes (CVD-REAL Nordic) When Compared with Dipeptidyl Peptidase-4 Inhibitor Therapy: A Multinational Observational Study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","article-title":"Comparative Risk Evaluation for Cardiovascular Events Associated with Dapagliflozin vs. Empagliflozin in Real-World Type 2 Diabetes Patients: A Multi-Institutional Cohort Study","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10070","DOI":"10.1038\/s41598-020-66668-5","article-title":"Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia with Sulfonylureas: An Experience with Conceptual Replication in Two Independent Populations","volume":"10","author":"Dhopeshwarkar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e3226","DOI":"10.1002\/dmrr.3226","article-title":"Hypoglycaemic Episodes Increase the Risk of Ventricular Arrhythmia and Sudden Cardiac Arrest in Patients with Type 2 Diabetes\u2014A Nationwide Cohort Study","volume":"36","author":"Hsieh","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e009115","DOI":"10.1161\/CIRCEP.120.009115","article-title":"Metformin Is Associated with a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study","volume":"14","author":"Ostropolets","year":"2021","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101299","DOI":"10.1016\/j.diabet.2021.101299","article-title":"Cardioprotective Effects of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylureas in Addition to Metformin: A Nationwide Cohort Study of Patients with Type 2 Diabetes","volume":"48","author":"Wang","year":"2022","journal-title":"Diabetes Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e026289","DOI":"10.1161\/JAHA.122.026289","article-title":"Sulfonylurea Is Associated with Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study","volume":"11","author":"Lee","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/cpt.2381","article-title":"Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies","volume":"111","author":"Dawwas","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"934193","DOI":"10.3389\/fcvm.2022.934193","article-title":"Electrocardiographic Changes Associated with SGLT2 Inhibitors and Non-SGLT2 Inhibitors: A Multi-Center Retrospective Study","volume":"9","author":"Wu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jhuo, S.-J., Lin, T.-H., Lin, Y.-H., Tsai, W.-C., Liu, I.-H., Wu, B.-N., Lee, K.-T., and Lai, W.-T. (2022). Clinical Observation of SGLT2 Inhibitor Therapy for Cardiac Arrhythmia and Related Cardiovascular Disease in Diabetic Patients with Controlled Hypertension. J. Pers. Med., 12.","DOI":"10.3390\/jpm12020271"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ehjcvp\/pvac043","article-title":"Use of Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Sudden Cardiac Arrest and for All-Cause Death in Patients with Type 2 Diabetes Mellitus","volume":"9","author":"Eroglu","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/dom.15000","article-title":"Sulphonylureas versus Metformin and the Risk of Ventricular Arrhythmias among People with Type 2 Diabetes: A Population-based Cohort Study","volume":"25","author":"Islam","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/cvr\/cvab271","article-title":"Cardiovascular Effects of Non-Insulin Glucose-Lowering Agents: A Comprehensive Review of Trial Evidence and Potential Cardioprotective Mechanisms","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of Glucose-Lowering Medications with Cardiovascular Outcomes: An Umbrella Review and Evidence Map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142021. Diabetes Care, 44, S111\u2013S124.","DOI":"10.2337\/dc21-S009"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes\u20142020. Diabetes Care, 43, S111\u2013S134.","DOI":"10.2337\/dc20-S010"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1760\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:04:03Z","timestamp":1760130243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["medicina59101760"],"URL":"https:\/\/doi.org\/10.3390\/medicina59101760","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]}}}